Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease.

Mahmoud Saif-Al-IslamUsama Mohamed AbdelaalMustafa Adel YounisHisham A Alghany AlgahlanSafaa Khalaf

Published in: Gastroenterology research and practice (2021)

Sofosbuvir-based DAA therapy is a highly effective and safe treatment regimen that results in the improvement of platelet count in thrombocytopenic patients, particularly in mild to moderate stages of hepatic fibrosis.

Keyphrases

hepatitis c virus
end stage renal disease
ejection fraction
human immunodeficiency virus
newly diagnosed
prognostic factors
stem cells
patient reported outcomes
bone marrow
hepatitis c virus infection
antiretroviral therapy